Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. OKUR
stocks logo

OKUR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent
Wall Street analysts forecast OKUR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OKUR is 25.50 USD with a low forecast of 17.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast OKUR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OKUR is 25.50 USD with a low forecast of 17.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.630
sliders
Low
17.00
Averages
25.50
High
34.00
Current: 2.630
sliders
Low
17.00
Averages
25.50
High
34.00
HC Wainwright & Co.
Robert Burns
Strong Buy
Maintains
$40 → $34
2025-03-18
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$40 → $34
2025-03-18
Maintains
Strong Buy
Reason
Oppenheimer
Matt Biegler
Buy
Maintains
$35 → $30
2025-03-11
Reason
Oppenheimer
Matt Biegler
Price Target
$35 → $30
2025-03-11
Maintains
Buy
Reason
Oppenheimer lowered the firm's price target on OnKure Therapeutics to $30 from $35 but keeps an Outperform rating on the shares after its Q4 results. The firm's post-earnings discussion with the company revealed that an important update from PIKture-01 is slated for the second half of 2025 and should provide enough data to make a determination on OKI-219's competitive profile relative to RLY-2608 and STX-478, the analyst tells investors in a research note. While OKI-219 is ultra-selective for common H1047R mutant, the company is also being more vocal about its pan-mutant inhibitor pipeline, the firm adds.
Jones Trading
Soumit Roy
Strong Buy
Initiates
$32
2025-01-28
Reason
Jones Trading
Soumit Roy
Price Target
$32
2025-01-28
Initiates
Strong Buy
Reason
Leerink Partners
Andrew Berens
Buy
Initiates
$33
2024-12-05
Reason
Leerink Partners
Andrew Berens
Price Target
$33
2024-12-05
Initiates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Onkure Therapeutics Inc (OKUR.O) is -0.56, compared to its 5-year average forward P/E of -1.54. For a more detailed relative valuation and DCF analysis to assess Onkure Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.54
Current PE
-0.56
Overvalued PE
0.29
Undervalued PE
-3.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
61.86
Current PS
0.00
Overvalued PS
160.49
Undervalued PS
-36.77
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

OKUR News & Events

Events Timeline

(ET)
2025-11-06
16:45:45
OnKure Therapeutics announces Q3 EPS of $1.09, below consensus estimate of $1.20
select
2025-08-12 (ET)
2025-08-12
16:34:22
OnKure Therapeutics reports Q2 EPS ($1.14), consensus ($1.25)
select
2025-05-06 (ET)
2025-05-06
07:32:55
OnKure Therapeutics sees cash runway into 4Q26
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
10-09TipRanks
VTI ETF Update, October 9, 2025

  • VTI Stock Performance: The Vanguard Total Stock Market ETF (VTI) has increased by 1.59% over the past week and 14.80% year-to-date, with a Moderate Buy consensus from analysts and a price target suggesting a 10.88% upside.

  • Holdings Analysis: VTI's top five holdings with the highest upside potential include Cibus, FibroBiologics, and Biodesix, while those with the greatest downside risk include Wolfspeed and Opendoor Technologies.

[object Object]
Preview
2.0
10-08TipRanks
VTI ETF Update, October 8, 2025

  • VTI Stock Performance: The Vanguard Total Stock Market ETF (VTI) has increased by 0.69% over the past week and 14.80% year-to-date, with a Moderate Buy consensus from analysts and a price target suggesting a 12.21% upside.

  • Holdings Analysis: VTI's top five holdings with the highest upside potential include Biodesix and Cibus, while those with the greatest downside risk include Wolfspeed and Opendoor Technologies; overall, VTI's Smart Score indicates it will likely perform in line with the market.

[object Object]
Preview
2.0
10-07TipRanks
VTI ETF Update, October 7, 2025

  • VTI Stock Performance: The Vanguard Total Stock Market ETF (VTI) has increased by 1.15% over the past week and 14.92% year-to-date, with a Moderate Buy rating from analysts and a price target suggesting an 11.18% upside.

  • Holdings Analysis: VTI's top five holdings with the highest upside potential include Cibus and Biodesix, while those with the greatest downside risk include Wolfspeed and GoPro.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Onkure Therapeutics Inc (OKUR) stock price today?

The current price of OKUR is 2.63 USD — it has increased 0.38 % in the last trading day.

arrow icon

What is Onkure Therapeutics Inc (OKUR)'s business?

OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a pipeline of tumor-agnostic candidates. It is developing OKI-219, a selective PI3KaH1047R inhibitor, as its lead program. It is engaged in targeting oncogenic PI3Ka and has multiple programs designed to enable targeting of this key oncogene. It is focused on delivering highly selective drug candidates that preserve wild-type PI3Ka while targeting the PI3Ka-mutated cancers, initially in advanced breast cancer. Its lead product candidate, OKI-219, is advancing in a phase I clinical trial. It also focuses on a development candidate targeting the most common PI3Ka mutations, such as H1047R, E545K, and E542K. Additionally, it is developing an allosteric inhibitor molecule.

arrow icon

What is the price predicton of OKUR Stock?

Wall Street analysts forecast OKUR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OKUR is 25.50 USD with a low forecast of 17.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Onkure Therapeutics Inc (OKUR)'s revenue for the last quarter?

Onkure Therapeutics Inc revenue for the last quarter amounts to -15.50M USD, increased 232.35 % YoY.

arrow icon

What is Onkure Therapeutics Inc (OKUR)'s earnings per share (EPS) for the last quarter?

Onkure Therapeutics Inc. EPS for the last quarter amounts to -13043000.00 USD, increased 471.81 % YoY.

arrow icon

What changes have occurred in the market's expectations for Onkure Therapeutics Inc (OKUR)'s fundamentals?

The market is revising No Change the revenue expectations for OnKure Therapeutics, Inc. (OKUR) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -4.36%.
arrow icon

How many employees does Onkure Therapeutics Inc (OKUR). have?

Onkure Therapeutics Inc (OKUR) has 46 emplpoyees as of December 05 2025.

arrow icon

What is Onkure Therapeutics Inc (OKUR) market cap?

Today OKUR has the market capitalization of 35.63M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free